Comparative breast tumor imaging to identify the expression of type I IGF receptor (IGF1R) by anti-IGF1R antibody-conjugated small molecule fluorophore or quantum dotsin vivo.

Author(s):  
H Zhang ◽  
X Zeng ◽  
D Yee
2009 ◽  
Vol 101 (1) ◽  
pp. 71-79 ◽  
Author(s):  
H Zhang ◽  
X Zeng ◽  
Q Li ◽  
M Gaillard-Kelly ◽  
C R Wagner ◽  
...  

1999 ◽  
Vol 276 (4) ◽  
pp. R1164-R1171 ◽  
Author(s):  
K. M. Kelley ◽  
T. R. Johnson ◽  
J. Ilan ◽  
R. W. Moskowitz

Nonresponsiveness to the growth-stimulatory actions of insulin-like growth factor (IGF)-I in chondrocytes has been reported in a number of disease states associated with impaired glucose metabolism. Primary rabbit chondrocytes were investigated for changes in their IGF response system [type-I IGF receptor and IGF-binding protein (IGFBP) expression] and in their ability to mount a synthetic response to IGF-I [as35S-labeled proteoglycan ([35S]PG) production] in media containing varying ambient glucose concentrations. Whereas basal [35S]PG synthetic rate was unaffected by glucose concentration, synthetic responsiveness to IGF-I was lost in media containing <5 mmol/l glucose or in media containing a “diabetic” glucose concentration (25 mmol/l). IGFBP expression, as measured by Northern analysis of mRNA levels and Western ligand blotting of secreted protein levels, was not significantly altered in the different glucose media, nor were there any differences in the cell surface localization of IGFBPs as assessed by affinity cross-linking with 125I-labeled IGF-I, suggesting that IGFBPs do not induce the IGF-I resistance. The nonresponsiveness to IGF-I in reduced glucose occurred with 25–50% reductions in steady-state levels of IGF type-I receptor mRNA and protein. A significant correlation between IGF receptor mRNA level and synthetic response to IGF-I was observed between 0 and 10 mmol/l glucose concentrations, suggesting that the loss of responsiveness in reduced glucose is manifested at the level of transcription and/or receptor mRNA stability. In contrast, nonresponsiveness to IGF-I in chondrocytes in diabetic glucose concentrations occurred without changes in receptor mRNA and protein levels, suggesting that IGF-I resistance was due to post-ligand-binding receptor defects. It is proposed that IGF-I resistance in chondrocytes subjected to inappropriate glucose levels may constitute an important pathogenic mechanism in degenerative cartilage disorders.


1996 ◽  
Vol 66 (3) ◽  
pp. 191-196 ◽  
Author(s):  
Darren R. Hodgson ◽  
Felicity E.B. May ◽  
Bruce R. Westley

2008 ◽  
Vol 114 (2) ◽  
pp. 277-285 ◽  
Author(s):  
Hua Zhang ◽  
Deepali Sachdev ◽  
Chun Wang ◽  
Allison Hubel ◽  
Martine Gaillard-Kelly ◽  
...  

1994 ◽  
Vol 12 (1) ◽  
pp. 3-12 ◽  
Author(s):  
D G Armstrong ◽  
C O Hogg

ABSTRACT An RNase protection assay is described that allowed the quantitative analysis of chicken type-I IGF receptor mRNA transcripts. The transcripts were measured in extracts of total nucleic acid (TNA) and, under the hybridization conditions described, protected probes of the expected size were obtained. The RNA-RNA hybrids could be quantified in the presence of at least a 1000-fold molar excess of DNA containing sequences which were complimentary to the RNA probe. The amount of protected probe was linearly related to the amount of TNA in the hybridization reaction medium, and this allowed the results to be expressed in the form of mRNA molecules/cell. Type-I IGF receptor mRNA transcripts were detected in all the tissues examined from a 20day-old chick embryo. Their amount ranged from 5 to 24 molecules/cell, in the order liver<breast muscle<leg muscle<heart<brain. The amount of receptor mRNA was 65- to 300-fold less than that of β-actin mRNA. The quantity of type-I IGF receptor mRNA varied significantly throughout embryonic and post-hatch development. Maximum amounts were measured in 21-day-old embryos (a two- to fourfold increase relative to 16-day-old embryos). Thereafter the amount of receptor mRNA decreased, during the 4-week period after hatching, to levels which were significantly lower than that observed in 16-day-old embryos. Throughout the period of embryonic and post-hatch development described here the amount of β-actin mRNA remained constant, indicating that the changes in the quantity of receptor mRNA were due to specific mechanisms acting directly on the steady-state levels of type-I IGF receptor mRNA. Selection for increased growth had no effect on the amount of type-I IGF receptor mRNA. The result was the same when expressed either as molecules/cell or as a percentage of β-actin mRNA.


1993 ◽  
Vol 136 (2) ◽  
pp. 191-198 ◽  
Author(s):  
T. A. Anderson ◽  
L. R. Bennett ◽  
M. A. Conlon ◽  
P. C. Owens

ABSTRACT The presence of insulin-like growth factor-I (IGF-I)-related molecules and IGF-binding factors in blood from golden perch, Macquaria ambigua, an Australian native freshwater fish, was investigated. Serum was acidified to dissociate IGF and IGF-binding protein complexes that might be present, and fractionated by size-exclusion high-performance liquid chromatography at pH 2·8. Fractions were neutralized and their activities assessed by (i) an immunoassay for mammalian IGF-I which also detects chicken IGF-I but in which all known forms of IGF-II react very poorly, (ii) a receptor assay for IGF-II in which all known forms of IGF-I react poorly, and (iii) a type-I IGF receptor assay in which mammalian IGF-I and IGF-II polypeptides are almost equivalent. No IGF-II-like activity was detected. Three peaks of IGF-I-like activity were detected by IGF-I immunoassay and type-I IGF receptor assay. The major peak of activity was similar in molecular size to human IGF-binding protein-3, 45–55 kDa ('large IGF'), and a minor peak of activity which was similar in size to mammalian IGFs, 7·5 kDa. A third peak of activity was observed eluting at a time which indicates that it is a smaller molecule than any previously described IGF. The large IGF was temperature-sensitive, but was not a binding protein for 125I-labelled human IGF-I (hIGF-I). This material therefore was able to bind to anti-hIGF-I antibodies and to human type-I IGF receptors, and may represent the fish equivalent of mammalian prepro-IGFs. The two smallest forms of IGF activity identified by IGF-I radioimmunoassay and type-I radioreceptor assay following acidic size-exclusion chromatography were able to stimulate protein synthesis by L-6 myoblasts in culture, although large IGF did not. When fresh (but not frozen and thawed) golden perch serum was incubated with 125I-labelled hIGF-I and then fractionated by size-exclusion liquid chromatography at pH 7·4 through Sephadex G-100, the radioactivity became associated with a complex, intermediate in size between free IGF-I and the major IGF-binding protein in human serum. The association of 125I-labelled hIGF-I with the complex was inhibited by the presence of unlabelled hIGF-I in the incubation. These studies show that receptor-active, immunoreactive and bioactive IGF-I-like activity is present in golden perch serum, and demonstrate the presence of an IGF-I-binding factor in this species. Journal of Endocrinology (1993) 136, 191–198


Sign in / Sign up

Export Citation Format

Share Document